{"id":"W2793526309","doi":"10.1016/s1474-4422(18)30069-3","title":"Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension","year":2018,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":337,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ottawa Hospital; NeuroRx Research (Canada); University of Ottawa; Montreal Neurological Institute and Hospital","funders":"Actelion Pharmaceuticals; Genentech; Acorda Therapeutics; Celgene; Biogen; Sanofi Genzyme; American Academy of Neurology; Bayer HealthCare; Sanofi; National Institute of Neurological Disorders and Stroke; Teva Pharmaceutical Industries; Novartis Pharma; EMD Serono; Ministry of Education; Novartis; Chugai Pharmaceutical; Roche; Genzyme; Pfizer; Amgen; MedDay Pharmaceuticals; National Multiple Sclerosis Society","keywords":"Natalizumab; Multiple sclerosis; Open label; Medicine; Placebo; Double blind; Disease; Clinical trial; Internal medicine; Pathology; Alternative medicine; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001921495,0.002629066,0.005085369,0.000659979,0.0006760326,0.001238366,0.001233379,0.002777654,0.006455176],"category_scores_gemma":[0.00170046,0.0008616298,0.003429267,0.0004697102,0.001822084,0.001861608,0.0004877462,0.004547743,0.001386517],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007553135,"about_ca_system_score_gemma":0.0009958469,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00120889,"about_ca_topic_score_gemma":0.002159904,"domain_scores_codex":[0.9992787,0.0003298649,0.00005338571,0.0001311679,0.00006987627,0.0001369781],"domain_scores_gemma":[0.9990357,0.000304828,0.0001737469,0.00009196949,0.00007467766,0.0003190244],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9875507,0.002638296,0.0001568467,0.000500257,0.0005521349,0.0000234285,0.00003033641,0.0001341741,0.001355846,0.00005990385,0.000330212,0.00666788],"study_design_scores_gemma":[0.9662922,0.03183397,0.0007241552,0.0000270495,0.0003620808,0.00001703521,0.00001368694,0.0001620375,0.0002434146,0.00007480033,0.0002380189,0.00001154378],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9798192,0.01030081,0.0008753711,0.0008273036,0.001286372,0.003047424,0.001272238,0.0002304386,0.00234091],"genre_scores_gemma":[0.9829883,0.004809062,0.002085924,0.001089154,0.0008535891,0.003729851,0.001208584,0.00004359704,0.003191939],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006455176,"threshold_uncertainty_score":0.02159476,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1127130527398965,"score_gpt":0.4109636813498584,"score_spread":0.2982506286099619,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}